Literature DB >> 12468921

Transient abnormal myelopoiesis in Noonan syndrome.

Ferraris Silvio1, Lanza Carlo, Barisone Elena, Bertorello Nicoletta, Farinasso Daniela, Miniero Roberto.   

Abstract

An infant affected by Noonan syndrome and presenting with abnormal hemopoiesis is described. Cytogenetic analysis, molecular studies, and in vitro culture assays ruled out myelodysplasia or other hematologic malignancies but were consistent with transient abnormal myelopoiesis. At present, 3 years and 10 months after diagnosis, the patient shows a normal hematologic picture. Supportive treatment in such patients, unless refractory cytopenias or overt leukemia develops, is emphasized.

Entities:  

Mesh:

Year:  2002        PMID: 12468921     DOI: 10.1097/00043426-200212000-00017

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  6 in total

1.  Noonan syndrome with leukaemoid reaction and overproduction of catecholamines: a case report.

Authors:  Tatsuro Kondoh; Eiich Ishii; Yoko Aoki; Takashi Shimizu; Masafumi Zaitsu; Yoichi Matsubara; Hiroyuki Moriuchi
Journal:  Eur J Pediatr       Date:  2003-05-09       Impact factor: 3.183

2.  Molecular basis of juvenile myelomonocytic leukemia.

Authors:  Andrica C H de Vries; C Michael Zwaan; Marry M van den Heuvel-Eibrink
Journal:  Haematologica       Date:  2010-02       Impact factor: 9.941

Review 3.  Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations.

Authors:  Nao Yoshida; Sayoko Doisaki; Seiji Kojima
Journal:  Paediatr Drugs       Date:  2012-06-01       Impact factor: 3.022

4.  The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease.

Authors:  Christian P Kratz; Charlotte M Niemeyer; Robert P Castleberry; Mualla Cetin; Eva Bergsträsser; Peter D Emanuel; Henrik Hasle; Gabriela Kardos; Cornelia Klein; Seiji Kojima; Jan Stary; Monika Trebo; Marco Zecca; Bruce D Gelb; Marco Tartaglia; Mignon L Loh
Journal:  Blood       Date:  2005-05-31       Impact factor: 22.113

5.  Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation.

Authors:  Marjolijn C J Jongmans; Ineke van der Burgt; Peter M Hoogerbrugge; Kees Noordam; Helger G Yntema; Willy M Nillesen; Roland P Kuiper; Marjolijn J L Ligtenberg; Ad Geurts van Kessel; J Han J M van Krieken; Lambertus A L M Kiemeney; Nicoline Hoogerbrugge
Journal:  Eur J Hum Genet       Date:  2011-03-16       Impact factor: 4.246

6.  Identification of novel biomarkers for prediction of neurological prognosis following cardiac arrest.

Authors:  Jung Woo Eun; Hee Doo Yang; Soo Hyun Kim; Sungyoup Hong; Kyu Nam Park; Suk Woo Nam; Sikyoung Jeong
Journal:  Oncotarget       Date:  2017-03-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.